Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Amy McBride Wendell

At a glance: Amy McBride Wendell is Director at Axogen (AXGN). Their latest SEC Form 4, filed Aug 12, 2026, reported a sale of $647K. On file: 1 purchase line ($100K) and 5 sale lines ($2.0M).

Disclosed holdings: about $6.0M of AXGN stock: 107,976 shares reported on their latest Form 4 (filed Aug 12, 2026), valued at the Nov 20, 2026 close of $55.73. This counts only AXGN shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

Director at Axogen, Inc. (AXGN); Director at Solventum Corp (SOLV)

Purchase track record

Not enough history. Based on 1 purchase with a full 90 days of price history.

—
Avg. 90-day return+21.9%
vs. S&P 500+12.7%
Beat the market100%
Paper profit on buys+$26K
Total bought / sold$100K / $2.0M

Amy McBride Wendell's InsiderPrint

7 trades from SEC Form 4 filings, 2023 to 2026, drawn as one fingerprint.

InsiderPrint of Amy McBride Wendell: 7 trades, 2023 to 20262023: 1 buy, 0 sales2024: 0 buys, 0 sales2025: 0 buys, 3 sales2026: 1 buy, 2 sales

Reading this print: Mostly sells, trading about 2 times a year, typically $147K a trade.

  • Bump outward: a purchase (2)
  • Dent inward: a sale (5)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Jason HarinsteinDirector · LUCK · 94% match
  2. Jim H. SnabeDirector · AI · 93% matchTheir buys since 2021: 1 of 3 beat the S&P 500
  3. Al J. HirshbergDirector · NE · 92% match
  4. Adam R. CraigChair · XFOR · 92% match
  5. Anthony S. GibneySee Remarks · AURA · 92% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Every purchase since 2023

From the SEC's insider data sets: each open-market buy by Amy McBride Wendell, matched to how the stock did over the next 90 days against the S&P 500.

1 of 1 buy beat the S&P 500 (100%), median +29.8% vs. the index. Small sample: treat with care. All insider buys: 46%.

StockFiled90 days vs. S&P 500
AXGNSep 8, 2023+29.8%

Buys made close together in one stock count once. Price-only returns; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Aug 12SEC AXGNAxogen, Inc. Sell Plan 13,353107,976 held (−11%) $48.42 $647K +15.1%
May 12SEC AXGNAxogen, Inc. Sell 1,64793,826 held (−2%) $42.60 $70K +30.8%
Mar 11SEC SOLVSolventum CorpFirst buy Buy 1,4755,039 held (+41%) $68.03 $100K +25.7%
Dec 17SEC AXGNAxogen, Inc. Sell 5,000132,510 held (−4%) $29.31 $147K +90.1%
Dec 17SEC AXGNAxogen, Inc. Sell 20,436112,074 held (−15%) $29.31 $599K +90.1%
Dec 17SEC AXGNAxogen, Inc. Sell 18,24893,826 held (−16%) $29.31 $535K +90.1%
  • Sell

    Director Amy Mcbride Wendell sold $647K of AXGN at $48.42 — pre-scheduled 10b5-1 plan sale.

  • Buy

    Director Amy Mcbride Wendell bought $100K of SOLV at $68.03 — first open-market purchase in our records; raises the stake by 41%.

Follow Amy McBride Wendell

Get one email when Amy McBride Wendell files a new purchase or sale. Free.

At most one email a day about Amy McBride Wendell, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.